Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a ...

Fintel reports that on November 13, 2024, JMP Securities downgraded their outlook for Syros Pharmaceuticals (NasdaqGS:SYRS) ...

Syros Pharmaceuticals (SYRS – Research Report) received a Hold rating and price target from JMP Securities analyst Jason Butler today.

Syros Pharmaceuticals (SYRS – Research Report) received a Hold rating and price target from TD Cowen analyst Phil Nadeau yesterday. The ...

Syros Pharmaceuticals' Phase 3 trial of tamibarotene in higher-risk myelodysplastic syndrome did not meet primary endpoints, ...

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that the ...

The SELECT-MDS-1 trial showed no significant complete response rate improvement with tamibarotene plus azacitidine for ...

Syros Pharmaceuticals announced that its phase 3 trial of tamibarotene in combination with azacitidine did not meet the primary endpoint for the treatment of myelodysplastic syndrome.

Operator: Good morning, and welcome to the Syros Pharmaceuticals Third Quarter 2024 Financial Results Conference Call. At ...

These are exciting times at Syros as we are nearing the pivotal data ... there remains a tremendous unmet need for higher-risk MDS patients whose disease is often progressive and associated ...

The American College of Lifestyle Medicine (ACLM) has announced that Nathan Pritikin, the nutritionist, inventor and longevity researcher known for pioneering lifestyle approaches to the treatment and ...